Underutilized Canadian wild berries as potential sources of lipophilic bioactive compounds with antihypertensive properties.

Traditional berries are small fruits and are widely distributed in the Canadian prairies. The current study investigates the lipophilic bioactive compounds such as fatty acids, phytosterols, and terpenes, and their bioactivities, such as lipid peroxidation, as well as the antihypertensive activities of fourteen underutilized Canadian wild berries. These berries include Saskatoon berries (Amelanchier alnifolia), gooseberries (Ribes hirtellum), wild grapes (Vitis riparia), blackcurrants (Ribes nigrum), redcurrants (Ribes rubrum), haskap berries (Lonicera caerulea), wild raspberries (Rubus idaeus), wild blueberries (Vaccinium angustifolium), chokeberries (Aronia melanocarpa), buckthorn (Rhamnus cathartica), highbush cranberries (Viburnum trilobum), chokecherries (Prunus virginiana), nannyberries (Viburnum lentago) and snowberries (Symphoricarpos albus). The fatty acids, phytosterols, and terpenes were identified using Gas Chromatography-Mass Spectrometry (GC-MS). Lipid peroxidation and the antihypertensive activity assessed by measuring the berries' angiotensin converting enzyme 1 (ACE1) inhibitory activity were determined using in vitro methods. Notably, wild grapes exhibited the highest (p < 0.05) total fat content (7659 ± 312 µg per g DW), followed by haskap berries (4650 ± 184 µg per g DW). Polyunsaturated fatty acids (PUFAs) were highest (p < 0.05) in wild grapes (74%). Predominant phytosterols and terpenes identified in Canadian wild berries included ß-sitosterol, isofucosterol, phytol, and α-amyrin. Saskatoon berries and gooseberries showed a distinct phytosterol and terpene profile compared to the other wild berries. Snowberries demonstrated the highest (p < 0.05) lipid peroxidation and the lowest (p < 0.05) angiotensin converting enzyme (ACE1) activity. This research provides valuable insights into the lipophilic bioactive compounds and their potential activities in vitro of the Canadian wild berries, offering a foundation for further exploration and potential applications in the context of nutraceuticals and functional foods.

Oat protein modulates cholesterol metabolism and improves cardiac systolic function in high fat, high sucrose fed rats.

Oats are recognized to provide many health benefits that are mainly associated with its dietary fibre, ß-glucan. However, the protein derived from oats is largely understudied with respect to its ability to maintain health and attenuate risk factors of chronic diseases. The goal of the current study was to investigate the metabolic effects of oat protein consumption in lieu of casein as the protein source in high fat, high sucrose (HF/HS) fed Wistar rats. Four-week-old rats were divided into three groups and were fed three different experimental diets: a control diet with casein as the protein source, an HF/HS diet with casein, or an HF/HS diet with oat protein for 16 weeks. Heart structure and function were determined by echocardiography. Blood pressure measurements, an oral glucose tolerance test, and markers of cholesterol metabolism, oxidative stress, inflammation, and liver and kidney damage were also performed. Our study results show that incorporation of oat protein in the diet was effective in preserving systolic heart function in HF/HS fed rats. Oat protein significantly reduced serum total and low-density lipoprotein cholesterol levels. Furthermore, oat protein normalized liver HMG-CoAR activity, which, to our knowledge, is the first time this has been reported in the literature. Therefore, our research suggests that oat protein can provide hypocholesterolemic and cardioprotective benefits in a diet-induced model of metabolic syndrome.

Genotypic and environmental variations in phenolic acid and avenanthramide content of Canadian oat (Avena sativa).

Phenolic compounds (PC) in oat may possess health promoting properties. This study evaluated the effect of genotype, environment, and their interaction on the phenolic acid and avenanthramide (AVN) concentration in Canadian oat. Six cultivars were grown at eight locations across Canada in a randomised complete block design with three field replicates. Free PCs were extracted from oat groat flour and analysed using a UPLC-PDA system. The cumulative concentration of free PCs and AVN ranged from 58 to 350 and 9 to 244 µg/g, respectively. The effect of environment was significant (p < 0.0001) for the concentration of all PCs. Cultivar differences significantly influenced the concentration of all PCs but AVNs A and B. The growing location explained > 68% of the variation in the concentration of AVN. Thus understanding the genotypic and environmental triggers of individual PCs may help agronomists and breeders strategize in selecting and growing oat cultivars of interest.

The effects of oat ingredients on blood pressure in spontaneously hypertensive rats.

This study investigated the blood pressure (BP) lowering and cardioprotective effects of oat avenanthramide C and beta-glucan alone or in combination in spontaneously hypertensive rats (SHR). Five-weeks-old male SHR and Wistar-Kyoto rats received vehicle, avenanthramide C and beta-glucan alone or a combination of avenanthramide C and beta-glucan via gavage for 15 weeks. BP was measured at 0, 10, and 15 weeks of treatment. Echocardiography was performed at 15 weeks of treatment. Oxidative stress and inflammation were also measured. Beta-glucan alone prevented the increase in systolic and diastolic BP in SHR, but avenanthramide C alone or the combination did not prevent the increase in systolic and diastolic BP. SHRs treated with beta-glucan and not avenanthramide C or the combination reduced isovolumetric relaxation time when compared to SHR treated with vehicle. Beta-glucan and avenanthramide C decreased the levels of malondialdehyde, a marker of oxidative stress in SHR. In conclusion, beta-glucan is a potential antihypertensive agent that may alleviate cardiovascular abnormalities. PRACTICAL APPLICATIONS: Oats products are believed to contain many bioactives that possess potential beneficial properties against chronic diseases. Specifically, oats beta-glucan has been well-established for its efficacy in positively modulating the risk factor for dyslipidemia. This preliminary in vivo study shows that beta-glucan is a potential antihypertensive agent that may alleviate cardiac dysfunction as well. In light of the current findings, further human studies may establish the efficacy of oats beta-glucan in hypertensive patients alongside the current antihypertensive medications. This novel attribute established via rigorous studies may provide an impetus for oats products and oats industry. Last but not least, it will also help improve the cardiovascular disease burden in a cost-effective way.